Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04325035 · ClinicalTrials.gov registry record · Phase 2
The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock
A Phase 2 study, sponsored by Windtree Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT04325035: Completed Phase 2 study, sponsored by Windtree Therapeutics.
NCT04325035 is a Phase 2 study that has completed, run by Windtree Therapeutics. The registered enrollment target is 90 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04325035, a Phase 2 study, has completed, sponsored by Windtree Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
This is a pilot, multinational, randomized, double-blind, placebo-controlled, 2-part safety and efficacy study. Subjects will consist of patients hospitalized for acute decompensated heart failure with persistent hypotension.
Primary Outcome
Change from baseline AUC for systolic blood pressure
Interventions
- DRUG Placebo
- DRUG Istaroxime
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2020-09-28 |
| Est. Completion | 2024-10-30 |
| Phase | Phase 2 |
What the finished NCT04325035 record still lists
NCT04325035 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04325035 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04325035 about?
NCT04325035 is a clinical study titled "The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock". This is a pilot, multinational, randomized, double-blind, placebo-controlled, 2-part safety and efficacy study. Subjects will consist of patients hospitalized for acute decompensated heart failure with persistent hypotension.
What is the current status of trial NCT04325035?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2020-09-28. Estimated completion is 2024-10-30.
What interventions are being tested in trial NCT04325035?
The interventions under investigation include: Placebo (DRUG), Istaroxime (DRUG).
Who is sponsoring clinical trial NCT04325035?
This trial is sponsored by Windtree Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04325035's enrollment target sits among peer trials
90 772nd of 2000 higher than 1,199 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI